Patent · US Active

Methods of using cytokine zalpha11 ligand

US7611699B2 · kind B2 · utility

5Cited by
5References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateOct 20, 2006
Grant dateNov 3, 2009
Priority date
Expiry dateApr 28, 2027

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.